Why Is BEAM THERAPEUTICS IN (BEAM) Stock Up Today?

Beam Therapeutics shares surged 15.58% to close at $28.78, driven by the release of initial Phase 1/2 clinical data for BEAM-301. The stock also benefited from a new FDA draft guidance that streamlines the approval process for patient-specific gene edits.

What Happened

Beam Therapeutics announced preliminary results from its ongoing Phase 1/2 trial evaluating BEAM-301, a one-time liver-targeted treatment for glycogen storage disease type Ia. In the 40 mg cohort, two patients achieved 15 hours of controlled fasting, with a safety profile consistent with other lipid nanoparticle-based therapies. The FDA simultaneously issued draft guidance allowing companies to file a single application covering multiple versions of the same gene-editing treatment, provided each aims for the same genetic correction.

H.C. Wainwright reiterated a Buy rating, noting the data strengthens confidence in the asset and maintaining an $80 price target. Wedbush maintained its Outperform rating but lowered its price target to $28.00.

What The Data Shows

The stock printed 64 fresh 52-week highs on October 28, 2026, extending a strong recent trend. Over the last eight sessions, BEAM has climbed 19.0%, moving from $24.19 to $28.78. The company remains unprofitable with a trailing twelve-month EPS of -0.84 and a net margin of -55.4%, though revenue has grown 158.9% over the same period. The stock carries a beta of 2.20 and a market capitalization of $2.4 billion.

Insider activity has been modestly bearish recently. CEO John M. Evans sold 50,000 shares on October 15, 2026, while SVP and Treasurer Bethany J. Cavanagh sold shares on October 1. These two transactions totaled $1.2 million, representing the only insider sales in the last 90 days.

What To Watch

Investors will monitor the broader implications of the FDA’s new draft guidance for gene-editing approvals. The stock’s recent momentum, including the cluster of 52-week highs, suggests continued volatility as the market digests the clinical data and regulatory updates.